 NEW YORK, March 04, 2021 GLOBE NEWSWIRE -- Renalytix AI plc LSE: RENX NASDAQ: RNLX, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that under the Companys Employee Share Purchase Plan the ESPP, new 17,652 ordinary shares of 0.0025 each in the capital of the Company the Ordinary Shares have been issued to settle the purchase of 8,826 American Depositary Shares, each representing two Ordinary Shares ADSs by employees who participated in the ESPP. Further details in relation to the ESPP were contained in the Companys announcement of 2 September 2020. 